Clinical Access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis

Hdl Handle:
http://hdl.handle.net/10144/314741
Title:
Clinical Access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis
Authors:
Conradie, Francesca; Meintjes, Graeme; Hughes, Jennifer; Maartens, Gary; Ferreira, Hannetjie; Siwendu, Sweetness; Master, Iqbal; Ndjeka, Norbert
Journal:
South African Medical Journal
Abstract:
While clinical disease caused by drug-sensitive Mycobacterium tuberculosis (MTB) can usually be treated successfully, clinical disease caused by drug-insensitive MTB is associated with a poorer prognosis. In December 2012, a new drug, bedaquiline, was approved by the US Food and Drug Administration. This article documents the process whereby the National Department of Health, Right to Care and Médecins Sans Frontières obtained access to this medication for South Africans who might benefit from subsequent implementation of the Clinical Access to Bedaquiline Programme
Publisher:
Health & Medical Publishing Group
Issue Date:
26-Mar-2014
URI:
http://hdl.handle.net/10144/314741
DOI:
10.7196/samj.7263
Additional Links:
http://samj.org.za/index.php/samj/article/view/7263
Language:
en
ISSN:
2078-5135; 0256-9574
Appears in Collections:
TB

Full metadata record

DC FieldValue Language
dc.contributor.authorConradie, Francescaen_GB
dc.contributor.authorMeintjes, Graemeen_GB
dc.contributor.authorHughes, Jenniferen_GB
dc.contributor.authorMaartens, Garyen_GB
dc.contributor.authorFerreira, Hannetjieen_GB
dc.contributor.authorSiwendu, Sweetnessen_GB
dc.contributor.authorMaster, Iqbalen_GB
dc.contributor.authorNdjeka, Norberten_GB
dc.date.accessioned2014-03-26T15:52:15Z-
dc.date.available2014-03-26T15:52:15Z-
dc.date.issued2014-03-26-
dc.identifier.citationClinical access to Bedaquiline programme for the treatment of drug-resistant tuberculosis 2014, 104 (3):164 South African Medical Journalen_GB
dc.identifier.issn2078-5135-
dc.identifier.issn0256-9574-
dc.identifier.doi10.7196/samj.7263-
dc.identifier.urihttp://hdl.handle.net/10144/314741-
dc.description.abstractWhile clinical disease caused by drug-sensitive Mycobacterium tuberculosis (MTB) can usually be treated successfully, clinical disease caused by drug-insensitive MTB is associated with a poorer prognosis. In December 2012, a new drug, bedaquiline, was approved by the US Food and Drug Administration. This article documents the process whereby the National Department of Health, Right to Care and Médecins Sans Frontières obtained access to this medication for South Africans who might benefit from subsequent implementation of the Clinical Access to Bedaquiline Programmeen_GB
dc.language.isoenen
dc.publisherHealth & Medical Publishing Groupen_GB
dc.relation.urlhttp://samj.org.za/index.php/samj/article/view/7263en_GB
dc.rightsPublished by: Health and Medical Publishing Group Archived on this site with kind permission of the Health and Medical Publishing Group and the South African Medical Association, [url]http://www.samj.org.za[/url]en_GB
dc.subjectAntibiotic Resistanceen_GB
dc.subjectHealth Policy/Access to Medecinesen_GB
dc.subjectTuberculosisen_GB
dc.titleClinical Access to Bedaquiline Programme for the treatment of drug-resistant tuberculosisen
dc.identifier.journalSouth African Medical Journalen_GB
All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.